STOCK TITAN

Alzamend Neuro: MGH ends bipolar trial statement of work

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Alzamend Neuro, Inc. (ALZN) said The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), terminated the bipolar-disorder trial’s statement of work on November 11, 2026. Alzamend had paused the trial on October 21 after FDA feedback on October 15 did not support its proposed eligibility expansion and said efficacy and safety trials may be more appropriate to support a New Drug Application. Alzamend expects a refund of approximately $25,000 for unused funds previously paid to MGH. The termination does not affect the healthy-subject trial or the master agreement.

Alzamend intends to request a Type B meeting for feedback on a revised AL001 development plan, which is expected to include ending Phase II trials and moving directly into a Phase III efficacy and safety trial in bipolar disorder. The company anticipates FDA feedback by the end of the second quarter of 2027. The healthy-subject trial’s clinical portion was completed in November 2025, with final results expected in December 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNovember 11, 2026: MGH terminated the bipolar-disorder trial’s statement of work.

Filing Explained

The master agreement contemplated five Phase II trials, but Alzamend says it had entered statements of work only for healthy subjects and bipolar disorder, leaving the other three without an entered statement of work at the time of this report.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Planned AL001 Phase II trials Five trials Planned for healthy subjects and patients with Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
BD Clinical Trial paused October 21, 2026 Alzamend paused the trial after receiving FDA feedback.
BD SOW termination November 11, 2026 MGH delivered written notice terminating the statement of work.
Refund of unused BD trial funds Approximately $25,000 Alzamend expects to receive the refund from MGH.
Anticipated FDA feedback By the end of the second quarter of 2027 Feedback sought through a planned Type B meeting on a revised clinical development plan.
Healthy-subject trial final results December 2026 Alzamend expects to announce the final results.
Type B meeting regulatory
"request a Type B meeting with the FDA"
A Type B meeting is a formal, scheduled discussion between a drug or medical-device developer and a health regulator to resolve key mid‑ or late‑stage development issues such as clinical trial plans, interpretation of results, or steps needed for approval. Like a mid‑project review with an inspector, the meeting’s outcome can meaningfully change the timeline, cost and risk for a candidate: a clear, positive outcome lowers uncertainty for investors, while requests for more data or changes can signal delays and extra expense.
New Drug Application regulatory
"trials may be more appropriate to support a New Drug Application"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
Phase II clinical trials medical
"ceasing Phase II trials of AL001"
Phase II clinical trials are studies that evaluate whether an experimental drug or therapy actually works and is reasonably safe in a larger group of patients after initial safety checks. Investors care because results provide the first meaningful evidence of effectiveness and side effects—like a prototype tested with real users—informing whether a program is likely to advance, shaping a drug’s future value and the company’s funding and partnership prospects.
Phase III efficacy and safety trial medical
"moving directly into a Phase III efficacy and safety trial in BD"
current good manufacturing practice technical
"current good manufacturing practice work"
Current good manufacturing practice (cGMP) are the up-to-date, enforced rules and standards that factories follow to make medicines, medical devices, and related products reliably safe and consistent. Think of it as a detailed recipe and factory checklist that covers cleanliness, equipment, staff training and record-keeping; meeting cGMP reduces the risk of recalls, regulatory shutdowns or lawsuits and thus protects product supply, company reputation and investor value.
adequate and well-controlled studies regulatory
"adequate and well-controlled studies capable of providing substantial evidence"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did ALZN pause its bipolar-disorder clinical trial?

Alzamend paused the trial after FDA feedback did not support its proposed eligibility expansion. MGH had reported challenging recruitment because the eligibility criteria excluded patients with certain co-morbidities that are highly prevalent in the patient population.

What is ALZN’s planned next step for AL001?

Alzamend intends to request a Type B meeting to seek FDA feedback on a revised clinical development plan. The plan is expected to include ending Phase II trials and moving directly into a Phase III efficacy and safety trial in bipolar disorder; the company anticipates feedback by the end of the second quarter of 2027.

How much unused money will ALZN receive from MGH?

Alzamend expects a refund of approximately $25,000 from MGH for funds previously paid in connection with the bipolar-disorder clinical trial but not used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001677077 false false false false 0001677077 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

____________________________________________________________

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

___________________________________________________________________

 

Date of Report (Date of earliest event reported):  November 17, 2026

 

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40483   81-1822909
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326

(Address of principal executive offices) (Zip Code)

 

(844) 722-6333

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common Stock, $0.0001 par value   ALZN   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

   
 

 

Item 8.01Other Information.

 

As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “Company”) entered into a Master Clinical Trial Agreement (the “Agreement”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“MGH”) to conduct five Phase II clinical trials of AL001. Each of the five trials, one in each of healthy subjects, patients afflicted with Alzheimer’s Disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), is intended to be covered by a separate statement of work (“SOW”) under the Agreement. To date, the Company has entered into a statement of work for healthy subjects (the “Healthy SOW”) and patients afflicted with BD (the “BD SOW”). In May 2025, the Company initiated the clinical trial relating to the Healthy SOW (the “Healthy Patient Clinical Trial”), which clinical portion was completed in November 2025.

 

In March 2026, the Company initiated the clinical trial relating to the BD SOW (the “BD Clinical Trial”). MGH subsequently advised the Company that recruitment had been challenging because the trial’s eligibility criteria excluded patients with certain co-morbidities, including diabetes, metabolic syndrome, cardiovascular disease and anxiety disorders, which are highly prevalent in this patient population. To improve enrollment, MGH asked that the Company modify the BD Clinical Trial’s eligibility criteria to include patients with such co-morbidities. The Company then made such request to the U.S. Food and Drug Administration (the “FDA”) to allow the Company to modify enrollment criteria. On October 15, 2026, the Company received written feedback from the FDA, in which the FDA did not support the proposed approach and indicated that efficacy and safety trials may be more appropriate to support a New Drug Application (an “NDA”). Specifically, the FDA stated that, “Based on the information you have submitted thus far, it does not appear that you are designing the aforementioned trials to be adequate and well-controlled studies that would be capable of providing substantial evidence of effectiveness for the proposed indications.”

 

In response, the Company paused the BD Clinical Trial on October 21, 2026 to further assess its options and determine the best path forward. Based on the written feedback from the FDA, the Company intends to request a Type B meeting with the FDA, which is a meeting typically held at key decision points in a drug’s development. Through this meeting, the Company will seek the FDA’s feedback on a revised clinical development plan, which is expected to include ceasing Phase II trials of AL001 and moving directly into a Phase III efficacy and safety trial in BD that would support an NDA. Specifically, the Company will ask the FDA to assess the results of the Healthy Patient Clinical Trial in the context of the Company’s completed clinical and nonclinical trials, and current good manufacturing practice work. The Company is preparing a briefing package in support of the Type B meeting and currently anticipates receiving the FDA’s feedback by the end of the second quarter of 2027.

 

In consultation with MGH, the Company considered adding additional healthy subjects to the BD Clinical Trial or moving to additional patient cohorts in the future planned clinical trials of MDD, PTSD and/or Alzheimer’s. Ultimately, the Company decided that, for efficiency purposes, it would not commit to any path forward on the BD Clinical Trial before receiving the FDA’s feedback. As a result, MGH then advised the Company that it could not keep the BD Clinical Trial paused for the anticipated period and would reassign the staff allocated to the study. On November 11, 2026, MGH delivered written notice to the Company terminating the BD SOW. The Company will receive a refund of approximately $25,000 from MGH of funds previously paid in connection with the BD Clinical Trial but not utilized.

 

The termination of the BD SOW has no impact on the Healthy SOW or the Healthy Patient Clinical Trial. The Company expects to finalize the clinical study report for the Healthy Patient Clinical Trial and to announce the final results in December 2026. In addition, the termination of the BD SOW has not impact on the Agreement, which otherwise remains in full and effect. Following the FDA’s feedback, the Company plans to pursue further clinical studies of AL001 in BD, MDD, PTSD and Alzheimer’s.

 

In accordance with General Instruction B.2 of Form 8-K, the information under this item shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

 

 -2- 
 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits:

 

Exhibit No.    Description
     
101   Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

 

 -3- 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ALZAMEND NEURO, INC.
   
   
Dated: November 17, 2026 /s/ Stephan Jackman  
 

Stephan Jackman

Chief Executive Officer

 

 

-4-

 

 

Filing Exhibits & Attachments

3 documents

Keep reading